Protective effect of maternal exposure to α-lipoic acid during pregnancy and lactation on susceptibility to OVAinduced neonatal asthma
Abstract
Purpose: To investigate the beneficial effect of alpha-lipoic acid (ALA) during pregnancy and lactation on susceptibility to ovalbumin (OVA)-induced neonatal asthma, and the mechanism of involved.
Methods: Pregnant BALB/c mice were administered ALA (1 % mixed with mouse chow) or standard mouse chow from 6th day of gestation to 21st day of lactation (postnatal). The offspring (neonatal pups) from the OVA and ALA+OVA groups were sensitized on 1st, 7th and 14th postnatal days (PNDs) via intraperitoneal (i.p.) injection of OVA (0.5 μg). Control mice pups were not exposed to OVA. On PND 21, all pubs were again exposed to 1 % OVA aerosol using a nebulizer.
Results: Neonatal mice exposed to ALA showed a significant decline (p < 0.05) in the number of inflammatory cells (eosinophils), levels of inflammatory markers (IL-4, IL-13, IL-5 and TNF-α) as well as OVA-specific IgE and total IgE, when compared to neonatal mice from pregnant mice that did not receive ALA (control). Moreover, the antioxidant profiles of ALA-treated mice offspring were significantly improved (p < 0.05). Marked downregulation (p < 0.05) of the protein expressions of NF-κB p-p65 subunit and TNF-α were observed in ALA-treated mice pups.
Conclusion: ALA exposure during pregnancy (maternal exposure) markedly decreases OVA-induced asthmatic airway inflammatory response in pups. Thus, ALA might be beneficial for use along with standard anti-asthmatic drugs in the management of pediatric asthmatic patients
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.